# US 2021/0275503 A1 · Targeting homologous recombination: a new sythetic lethal therapeutic paradigm

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275503 A1
- Document ID: US20210275503A1
- Status: Published application
- Kind: A1
- Application number: 17/191,220
- Filed: 2021-03-03
- Published: 2021-09-09
- Earliest claimed: 2020-03-03
- Applicants: Cyteir Therapeutics, Inc.
- Inventors: Thomas O'SHEA; Markus RENSCHLER; Todd BOWSER; Jean-Marc LAPIERRE; Kevin MILLS
- Web page: https://patentgrep.com/patent/US20210275503A1

## CPC

- A61K 31/426: 1,3-Thiazoles
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for its use, such as to treat cancer.

## Claims

### Claim 1

A method of treating a cancer comprising administering to a subject in need thereof Compound 67A
or a pharmaceutically acceptable salt thereof, at a dosage from about 15 mg to about 700 mg.

### Claim 2 (depends on 1)

The method of claim 1, wherein Compound 67A is administered at a dosage of about 15 mg.

### Claim 3 (depends on 1)

The method of claim 1, wherein Compound 67A is administered at a dosage of about 20 mg.

### Claim 4 (depends on 1)

The method of claim 1, wherein Compound 67A is administered at a dosage of about 30 mg.

### Claim 5 (depends on 1)

The method of claim 1, wherein Compound 67A is administered at a dosage of about 45 mg.

### Claim 6 (depends on 1)

The method of claim 1, wherein Compound 67A is administered at a dosage of about 90 mg.

### Claim 7 (depends on 1)

The method of claim 1, wherein Compound 67A is administered at a dosage of about 130 mg.

### Claim 8 (depends on 1)

The method of claim 1, wherein Compound 67A is administered at a dosage of about 200 mg.

### Claim 9 (depends on 1)

The method of claim 1, wherein Compound 67A is administered at a dosage of about 300 mg.

### Claim 10 (depends on 1)

The method of claim 1, wherein Compound 67A is administered at a dosage of about 400 mg.

### Claim 11 (depends on 1)

The method of claim 1, wherein Compound 67A is administered at a dosage of about 500 mg.

### Claim 12 (depends on 1)

The method of claim 1, wherein Compound 67A is administered at a dosage of about 600 mg.

### Claim 13 (depends on 1)

The method of claim 1, wherein Compound 67A is administered at a dosage of about 700 mg.

### Claim 14 (depends on 1)

The method of claim 1, wherein Compound 67A is administered at a dosage ranging from about 15 mg/day to about 1400 mg/day.

### Claim 15 (depends on 1)

The method of claim 1, wherein Compound 67A is administered at a dosage ranging from about 90 mg to about 700 mg, about 100 mg to about 200 mg, about 100 mg to about 300 mg, about 100 mg to about 400 mg, about 100 mg to about 500 mg, about 100 mg to about 600 mg, about 100 mg to about 700 mg, about 200 mg to about 300 mg, about 200 mg to about 400 mg, about 200 mg to about 500 mg, about 200 mg to about 600 mg, about 200 mg to about 700 mg, about 300 mg to about 400 mg, about 300 mg to about 500 mg, about 300 mg to about 600 mg, about 300 mg to about 700 mg, about 400 mg to about 500 mg, about 400 mg to about 600 mg, about 400 mg to about 700 mg, about 500 mg to about 600 mg, about 500 mg to about 700 mg, and about 600 mg to about 700 mg.

### Claim 16 (depends on 1)

The method of claim 1, wherein Compound 67A is administered at a dosage ranging from about 10 mg to about 50 mg, about 10 mg to about 40 mg, about 10 mg to about 30 mg, about 15 mg to about 50 mg, about 15 mg to about 40 mg, about 15 mg to about 30 mg, about 20 mg to about 50 mg, about 20 mg to about 40 mg, about 20 mg to about 30 mg, about 30 mg to about 50 mg, and about 30 mg to about 40 mg.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1-16, wherein Compound 67A is administered once daily.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1-16, wherein Compound 67A is administered twice daily.

### Claim at position 19

-24. (canceled)

### Claim 25 (depends on 1)

The method of claim 1, wherein the subject is human.

### Claim 26 (depends on 1)

The method of claim 1, wherein the cancer is B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukemia, multiple myeloma, breast cancer, head and neck cancer, soft tissue sarcoma, ovarian cancer, pancreatic cancer, follicular lymphoma, or mantle cell lymphoma.